Reduced expression of CD69 and adhesion molecules of T lymphocytes in asthmatic children receiving immunotherapy.
T lymphocytes play a fundamental role in the initiation and regulation of chronic inflammatory responses in patients with asthma. CD69 is an early marker of T-cell activation. The levels of intercellular adhesion molecule-1 (ICAM-1, CD54) and L-selectin have been reported to increase in patients with allergic diseases and asthma. The present study was therefore undertaken to investigate the expression of CD69, CD54, and L-selectin by T lymphocytes of children with asthma, before and after immunotherapy. Eighteen children newly diagnosed with asthma, 11 good and nine poor responders to immunotherapy, and 16 normal subjects, were enrolled in this study. The percentages of CD69+, CD54+, and CD62L+ cells in T lymphocytes were measured by using flow cytometry. The levels of CD69, CD54, and CD62L in serum and culture supernatants were determined by using enzyme-linked immunosorbent assay (ELISA). The expression of CD69 and CD54 on CD3+ T lymphocytes was significantly higher in children with asthma than in control patients. All the patient groups expressed (spontaneously and following stimulation with phorbol myristate acetate and ionomycin together with mite-extract proteins) greater amounts of CD69 and CD54 than did control subjects. With long-term immunotherapy, the percentages of CD69+ and CD54+ T lymphocytes were significantly lower in patients with a good response to immunotherapy. Our results also showed significantly lower serum L-selectin levels following immunotherapy. In conclusion, successful immunotherapy resulted in decreased expression and production of CD69 and CD54. These results may explain, in part, the clinical efficacy of immunotherapy.
Huang
Jing-Long
JL
Division of Allergy, Asthma and Rheumatology, Department of Pediatrics, Chang Gung Children's Hospital and Chang Gung University, Taoyuan, Taiwan.
Ou
Liang-Shiou
LS
Tsao
Ching-Hsiung
CH
Chen
Li-Chen
LC
Kuo
Ming-Ling
ML
D000293:Adolescent; D015703:Antigens, CD / Q000096:biosynthesis* / Q000187:drug effects; D000945:Antigens, Differentiation, T-Lymphocyte / Q000096:biosynthesis* / Q000187:drug effects; D001249:Asthma / Q000378:metabolism* / Q000628:therapy*; D015415:Biomarkers / Q000097:blood; D002273:Carcinogens / Q000494:pharmacology; D002648:Child; D002669:Child Welfare; D003888:Desensitization, Immunologic; D005260:Female; D005434:Flow Cytometry; D005500:Follow-Up Studies; D006801:Humans; D018799:Intercellular Adhesion Molecule-1 / Q000096:biosynthesis* / Q000097:blood / Q000187:drug effects; D015759:Ionomycin / Q000494:pharmacology; D007476:Ionophores / Q000494:pharmacology; D019041:L-Selectin / Q000096:biosynthesis* / Q000097:blood / Q000187:drug effects; D037181:Lectins, C-Type; D008297:Male; D012720:Severity of Illness Index; D013601:T-Lymphocytes / Q000187:drug effects / Q000378:metabolism*; D013624:Taiwan; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D016896:Treatment Outcome; D000099192:CD69 Antigens
D015703:Antigens, CD; D000945:Antigens, Differentiation, T-Lymphocyte; D015415:Biomarkers; D002273:Carcinogens; D018799:Intercellular Adhesion Molecule-1; D015759:Ionomycin; D007476:Ionophores; D019041:L-Selectin; D037181:Lectins, C-Type; D013755:Tetradecanoylphorbol Acetate; D000099192:CD69 Antigens